The objective of this study is to assess the safety and feasibility of allogeneic adipose tissue-derived mesenchymal stem cells (ASCs) injected into the lacrimal gland in a smaller groups of 7 patients with Aqueous Deficient Dry Eye Disease (ADDE)
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Pain at injection site: grade
Timeframe: 4 months after treatment
Infection at injection site
Timeframe: 4 months after treatment
Bleeding at injection site
Timeframe: 4 months after treatment
Eyelid function disorder
Timeframe: 4 months after treatment
Periorbital edema
Timeframe: 4 months after treatment
Ocular discomfort
Timeframe: 4 months after treatment
Flu-like symptoms
Timeframe: 4 months after treatment
Fever
Timeframe: 4 months after treatment